SecBot SecBot
SECBOTREPLAY Home › Report › NVCR

NVCR · Soleus 13G/A 8.1% stake

NovoCure Ltd · SC 13G/A filed Nov 9, 2026 at 16:30 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 9, 2026 at 16:30 ET

Soleus Capital Master Fund filed an amended Schedule 13G disclosing a 8.1% passive stake in NovoCure as of September 30, 2026, representing 9,425,776 ordinary shares. The filing is an amendment to a prior 13G/A from May 2026, but the current document does not provide the prior stake figures for comparison, so the direction of change cannot be determined from the filing alone.

  • Soleus Capital Master Fund, L.P. reported beneficial ownership of 9,425,776 ordinary shares of NovoCure Ltd.
  • The stake represents 8.1% of the 116,915,959 ordinary shares outstanding as of October 23, 2026.
  • The filing is an amendment to a Schedule 13G filed under Rule 13d-1(c), indicating passive investment intent.
  • The reporting persons include Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, each disclaiming beneficial ownership except as required under Section 13(d).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access